USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
U.S. Anticoagulant Market
U.S. Anticoagulant Market
RELEASE DATE
25-Apr-2006
25-Apr-2006
REGION
North America
North America
Research Code: F693-01-00-00-00
SKU: HC01495-NA-MR_06059
$4,950.00
In stock
SKU
HC01495-NA-MR_06059
Description
This research service analyzes the changing dynamics in the U.S. anticoagulant market for the period 2002-2012. Included are pipeline analysis, and individual segment revenue forecasts as well as selected major products. Both products currently in the market, as well as those forecast to enter the market by 2012 are included, with an emphasis on branded drug products. The market is segmented by product class: warfarin, heparins, direct thrombin inhibitors, synthetic pentasaccharides, and emerging anticoagulant products. The products covered in this research service are used in the treatment of diseases such as acute coronary syndromes, venous thromboembolism, stroke, and atrial fibrillation.
Table of Contents
Executive Summary
- Introduction
Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
Overview
- Introduction
- Disease Overview
- Coagulation Pathways and Testing
- Selected Procedures
- Market Engineering Measurements
General Market Trends
- Industry Issues and Challenges
- Market Drivers
- Market Restraints
Total Market Forecasts
- Revenue Forecasts
- Market Share Analysis
Competitive Structure
- Overview
Frost & Sullivan Awards
- Company of the Year Award
- Product Differentiation Innovation of the Year Award
- Industry Innovation and Advancement of the Year Award
- Brand Development Strategy Leadership of the Year Award
Overview
Market Forecasts
Overview
Market Forecasts
Overview
Market Forecasts
Overview
Market Forecasts
Overview
Market Forecasts
Decision Support Databases
Popular Topics
This research service analyzes the changing dynamics in the U.S. anticoagulant market for the period 2002-2012. Included are pipeline analysis, and individual segment revenue forecasts as well as selected major products. Both products currently in the market, as well as those forecast to enter the market by 2012 are included, with an emphasis on branded drug products. The market is segmented by product class: warfarin, heparins, direct thrombin inhibitors, synthetic pentasaccharides, and emerging anticoagulant products. The products covered in this research service are used in the treatment of diseases such as acute coronary syndromes, venous thromboembolism, stroke, and atrial fibrillation.
| No Index | Yes |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | F693-01-00-00-00 |
| Is Prebook | No |